Synapse - Find an Expert

115370 Results

People

Ladanyi
Motzer
Reuter
Scher
Brennan
Giralt
Gonen
Perales
Hudis
Jarnagin

Groups

Department of Medicine (39031)
GSK Faculty (22466)
Solid Tumor Oncology Division (22055)
Surgery (21246)
Sloan Kettering Institute Faculty (16085)
Survivorship Research (15761)
Center for Hematologic Malignancies (13261)
Hematologic Malignancies, Division of (13086)
Sloan Kettering Institute Postdocs (12935)
Department of Pathology and Laboratory Medicine (12608)

Results (115370)

Assessment of supporting evidence and postmarketing requirements for therapeutic indications with Real-Time Oncology Drug Review, 2018-2023

Meeting Abstract

Mooghali, M.; Mohammad, A.; Wallach, J. D.; Mitchell, A. P.; Ross, J. S.; Ramachandran, R.
Value in Health (2024)

Fulltext@MSK | Save

Can multi-cancer early detection screening result in early cancer detection? A modeling study

Meeting Abstract

Chhatwal, J.; Xiao, J.; Merdan, S.; El Habr, A.; Tyson, C.; Cao, X.; Raoof, S.; Fendrick, A. M.; Ozbay, A. B.; Limburg, P.; more...
Value in Health (2024)

Fulltext@MSK | Save

Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor

Meeting Abstract

Dai, D.; Tecson, K.; Pan; Ye, X.; Tap, W. D.
Value in Health (2024)

Fulltext@MSK | Save

Leveraging data aggregators to annotate deidentified genomic data derived from commercial laboratory specimens to study COVID-19 severity

Meeting Abstract

Dandiker, S.; Latham, A.; Tanpaiboon, P.; Ratajski, A. M.; Bare, L.; Chanock, S.; Fesko, Y. A.; Joseph, V.; Offit, K.
Value in Health (2024)

Fulltext@MSK | Save

Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma

Meeting Abstract

Zheng, D.
The Oncologist (2024)

Fulltext@MSK | Save

Unraveling the impact of tumor microenvironment on immunotherapy response/resistance in human sarcomatoid clear cell renal cell carcinoma: Insights from a novel mouse model

Meeting Abstract

Jiang, H.
The Oncologist (2024)

Fulltext@MSK | Save

Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post immune-oncology (IO) and vascular endothelial growth factor (VEGF) receptor targeted therapies

Meeting Abstract

Shah, N.; Sura, S.; Shinde, R.; Wentworth, C.; Conkling, P.; Bupathi, M.; Perini, R.; Vickery, D.; Motzer, R.
The Oncologist (2024)

Fulltext@MSK | Save

Tumor immune microenvironment determinants of response to Lenvatinib and aPD-1 blockade in clear cell renal cell carcinoma

Meeting Abstract

Vuong, L.
The Oncologist (2024)

Fulltext@MSK | Save

Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib

Meeting Abstract

Desai, J.; Wagner, A. J.; Garcia, I. C.; Cesari, M.; Gordon, M.; Lin, C. C.; Papai, Z.; Ryan, C. W.; Tap, W. D.; Trent, J. C.; more...
Value in Health (2024)

Fulltext@MSK | Save

Pre-surgical visceral adipose tissue may be a novel pre-surgical risk factor for acute kidney injury among clear cell renal cell cancer patients undergoing radical nephrectomy

Meeting Abstract

Sanchez, A.; Olson, L.; Knezevic, A.; Akin, O.; Scott, J. S.; Mourtzakis, M.; Hakimi, A. A.; Russo, P.; Jaimies, E.; Bradshaw, P.; more...
The Oncologist (2024)

Fulltext@MSK | Save